PubRank

Keith P Klugman

Author PubWeight™ 235.37‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Rapid pneumococcal evolution in response to clinical interventions. Science 2011 9.09
2 Antimicrobial resistance in developing countries. Part I: recent trends and current status. Lancet Infect Dis 2005 5.58
3 Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011 5.43
4 International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004 4.75
5 Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002 4.08
6 An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003 3.93
7 Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004 3.75
8 Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005 3.72
9 Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014 3.68
10 Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004 3.49
11 A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004 3.49
12 The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin Infect Dis 2005 2.81
13 Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010 2.50
14 Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis 2007 2.49
15 Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011 2.48
16 Density interactions among Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. Pediatr Infect Dis J 2013 2.47
17 Pneumococcal vaccination in developing countries. Lancet 2006 2.45
18 Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 2005 2.14
19 Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008 2.11
20 Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clin Infect Dis 2002 2.07
21 Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine 2007 2.07
22 Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007 2.06
23 Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 2005 2.05
24 Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis 2005 2.03
25 Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006 1.98
26 Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae--and associated interactions with Staphylococcus aureus and Haemophilus influenzae colonization--in HIV-Infected and HIV-uninfected children. J Infect Dis 2007 1.95
27 Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009 1.92
28 Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med 2014 1.84
29 Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis 2009 1.82
30 Increased risk of invasive bacterial infections in African people with sickle-cell disease: a systematic review and meta-analysis. Lancet Infect Dis 2010 1.82
31 Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med 2011 1.82
32 Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008 1.82
33 Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 2005 1.74
34 Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009 1.69
35 Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clin Infect Dis 2002 1.66
36 Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis 2011 1.63
37 Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother 2004 1.53
38 Pneumococcal vaccines and flu preparedness. Science 2007 1.50
39 The anticipated severity of a "1918-like" influenza pandemic in contemporary populations: the contribution of antibacterial interventions. PLoS One 2012 1.47
40 Emergence of fluoroquinolone-resistant Streptococcus pneumoniae in a South African child in a tuberculosis treatment facility. Pediatr Infect Dis J 2003 1.44
41 Pneumococcal capsular switching: a historical perspective. J Infect Dis 2012 1.43
42 Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2006 1.43
43 Serotype 6C is associated with penicillin-susceptible meningeal infections in human immunodeficiency virus (HIV)-infected adults among invasive pneumococcal isolates previously identified as serotype 6A in South Africa. Int J Antimicrob Agents 2008 1.40
44 Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis 2010 1.39
45 World Health Organisation definition of "radiologically-confirmed pneumonia" may under-estimate the true public health value of conjugate pneumococcal vaccines. Vaccine 2006 1.38
46 Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin. Antimicrob Agents Chemother 2004 1.36
47 Role of Streptococcus pneumoniae in hospitalization for acute community-acquired pneumonia associated with culture-confirmed Mycobacterium tuberculosis in children: a pneumococcal conjugate vaccine probe study. Pediatr Infect Dis J 2010 1.33
48 Influence of bacterial interactions on pneumococcal colonization of the nasopharynx. Trends Microbiol 2012 1.33
49 Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J 2005 1.31
50 A framework for global surveillance of antibiotic resistance. Drug Resist Updat 2011 1.29
51 Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. MBio 2014 1.26
52 Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis 2012 1.26
53 Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013 1.25
54 Epidemiology of Group B Streptococcus in developing countries. Vaccine 2013 1.24
55 Communicating trends in resistance using a drug resistance index. BMJ Open 2011 1.23
56 Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010 1.23
57 Lower respiratory tract infections associated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J 2002 1.22
58 Development of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa. PLoS One 2012 1.21
59 Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002 1.19
60 The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011 1.19
61 Neisseria meningitidis intermediately resistant to penicillin and causing invasive disease in South Africa in 2001 to 2005. J Clin Microbiol 2008 1.19
62 Analysis of penicillin-binding protein genes of clinical isolates of Streptococcus pneumoniae with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2002 1.16
63 Seasonality, incidence, and repeat human metapneumovirus lower respiratory tract infections in an area with a high prevalence of human immunodeficiency virus type-1 infection. Pediatr Infect Dis J 2007 1.16
64 In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2008 1.16
65 Human metapneumovirus genetic variability, South Africa. Emerg Infect Dis 2005 1.15
66 Human metapneumovirus-associated lower respiratory tract infections among hospitalized human immunodeficiency virus type 1 (HIV-1)-infected and HIV-1-uninfected African infants. Clin Infect Dis 2003 1.14
67 Bacterial pathogens and death during the 1918 influenza pandemic. N Engl J Med 2009 1.14
68 Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. Pediatr Infect Dis J 2003 1.14
69 Efficacy of whole-cell killed bacterial vaccines in preventing pneumonia and death during the 1918 influenza pandemic. J Infect Dis 2010 1.11
70 Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. AIDS 2010 1.11
71 Pneumococcal coinfection with human metapneumovirus. J Infect Dis 2006 1.09
72 Fluoroquinolone-resistant Streptococcus pneumoniae. Emerg Infect Dis 2006 1.08
73 Novel role for the Streptococcus pneumoniae toxin pneumolysin in the assembly of biofilms. MBio 2013 1.08
74 Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. PLoS One 2011 1.08
75 Recommendations for treatment of childhood non-severe pneumonia. Lancet Infect Dis 2009 1.07
76 The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 2012 1.07
77 The future of pneumococcal disease prevention. Vaccine 2011 1.06
78 Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005 1.06
79 Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones. J Antimicrob Chemother 2002 1.05
80 The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis 2002 1.04
81 Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. Vaccine 2013 1.04
82 Susceptibility of Yersinia pestis to novel and conventional antimicrobial agents. J Antimicrob Chemother 2003 1.03
83 Variable recombination dynamics during the emergence, transmission and 'disarming' of a multidrug-resistant pneumococcal clone. BMC Biol 2014 1.03
84 The LuxS-dependent quorum-sensing system regulates early biofilm formation by Streptococcus pneumoniae strain D39. Infect Immun 2011 1.02
85 Vaccines as tools against resistance: the example of pneumococcal conjugate vaccine. Semin Pediatr Infect Dis 2004 1.02
86 Quorum-sensing systems LuxS/autoinducer 2 and Com regulate Streptococcus pneumoniae biofilms in a bioreactor with living cultures of human respiratory cells. Infect Immun 2013 1.01
87 Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. Pediatr Infect Dis J 2006 1.01
88 The multidrug-resistant PMEN1 pneumococcus is a paradigm for genetic success. Genome Biol 2012 1.01
89 Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 2009 1.00
90 Time from illness onset to death, 1918 influenza and pneumococcal pneumonia. Emerg Infect Dis 2009 1.00
91 Conserved mutations in the pneumococcal bacteriocin transporter gene, blpA, result in a complex population consisting of producers and cheaters. MBio 2011 1.00
92 Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. J Clin Virol 2006 0.99
93 Invasive pneumococcal pneumonia and respiratory virus co-infections. Emerg Infect Dis 2012 0.97
94 Live attenuated influenza vaccine, but not pneumococcal conjugate vaccine, protects against increased density and duration of pneumococcal carriage after influenza infection in pneumococcal colonized mice. J Infect Dis 2013 0.97
95 Site-specific mutagenesis analysis of PBP 1A from a penicillin-cephalosporin-resistant pneumococcal isolate. Antimicrob Agents Chemother 2003 0.96
96 HIV and influenza virus infections are associated with increased blood pneumococcal load: a prospective, hospital-based observational study in South Africa, 2009-2011. J Infect Dis 2013 0.96
97 Antibiotic non-susceptibility among Streptococcus pneumoniae and Haemophilus influenzae isolates identified in African cohorts: a meta-analysis of three decades of published studies. Int J Antimicrob Agents 2013 0.96
98 Meningococcal disease in South Africa, 1999-2002. Emerg Infect Dis 2007 0.95
99 Expression of Streptococcus pneumoniae Virulence-Related Genes in the Nasopharynx of Healthy Children. PLoS One 2013 0.95
100 Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome. J Infect 2007 0.95
101 Interspecies recombination in type II topoisomerase genes is not a major cause of fluoroquinolone resistance in invasive Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother 2005 0.94
102 Interrelationship of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus colonization within and between pneumococcal-vaccine naïve mother-child dyads. BMC Infect Dis 2013 0.94
103 Gender as a risk factor for both antibiotic resistance and infection with pediatric serogroups/serotypes, in HIV-infected and -uninfected adults with pneumococcal bacteremia. J Infect Dis 2004 0.94
104 Amino acid mutations essential to production of an altered PBP 2X conferring high-level beta-lactam resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2005 0.94
105 The role of influenza and parainfluenza infections in nasopharyngeal pneumococcal acquisition among young children. Clin Infect Dis 2014 0.93
106 Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 2003 0.93
107 Long-term antibody levels and booster responses in South African children immunized with nonavalent pneumococcal conjugate vaccine. Vaccine 2004 0.93
108 Distribution of factor H binding protein beyond serogroup B: variation among five serogroups of invasive Neisseria meningitidis in South Africa. Vaccine 2010 0.93
109 Global practices of meningococcal vaccine use and impact on invasive disease. Pathog Glob Health 2014 0.91
110 Increased risk of death in human immunodeficiency virus-infected children with pneumococcal meningitis in South Africa, 2003-2005. Pediatr Infect Dis J 2011 0.91
111 Use of 2 pneumococcal common protein real-time polymerase chain reaction assays in healthy children colonized with Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2011 0.90
112 Systemic shigellosis in South Africa. Clin Infect Dis 2012 0.90
113 Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr Infect Dis J 2002 0.89
114 Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine 2011 0.89
115 Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: the dynamics of PCV13 vaccine uptake. Vaccine 2013 0.89
116 Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1-infected and -uninfected children. Pediatr Infect Dis J 2002 0.88
117 Use of procalcitonin and C-reactive protein to evaluate vaccine efficacy against pneumonia. PLoS Med 2005 0.88
118 Dynamics of pneumococcal transmission in vaccine-naive children and their HIV-infected or HIV-uninfected mothers during the first 2 years of life. Am J Epidemiol 2013 0.88
119 Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J 2013 0.88
120 Antimicrobial susceptibility and molecular epidemiology of Streptococcus pneumoniae isolated from Shanghai, China. Int J Antimicrob Agents 2008 0.88
121 High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2007 0.88
122 Interspecies recombination occurs frequently in quinolone resistance-determining regions of clinical isolates of Streptococcus pyogenes. Antimicrob Agents Chemother 2008 0.88
123 Herd immunity after pneumococcal conjugate vaccination. Lancet 2007 0.87
124 Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Vaccine 2011 0.87
125 Introduction: historical perspective and development of amoxicillin/clavulanate. Int J Antimicrob Agents 2007 0.86
126 Altered PBP 2A and its role in the development of penicillin, cefotaxime, and ceftriaxone resistance in a clinical isolate of Streptococcus pneumoniae. Antimicrob Agents Chemother 2005 0.86
127 Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine 2004 0.86
128 An unusual pneumococcal sequence type is the predominant cause of serotype 3 invasive disease in South Africa. J Clin Microbiol 2009 0.86
129 Risk factors for multidrug-resistant invasive pneumococcal disease in South Africa, a setting with high HIV prevalence, in the prevaccine era from 2003 to 2008. Antimicrob Agents Chemother 2012 0.86
130 Interaction between influenza virus and Streptococcus pneumoniae in severe pneumonia. Expert Rev Respir Med 2008 0.85
131 Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial. Pediatr Infect Dis J 2002 0.85
132 Acquisition of Streptococcus pneumoniae in pneumococcal conjugate vaccine-naïve South African children and their mothers. Pediatr Infect Dis J 2013 0.85
133 Prevalence of first-step mutants among levofloxacin-susceptible invasive isolates of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2006 0.85
134 Pathogen replication, host inflammation, and disease in the upper respiratory tract. Infect Immun 2013 0.84
135 The remaining challenge of pneumonia: the leading killer of children. Pediatr Infect Dis J 2011 0.84
136 Economic burden of acute lower respiratory tract infection in South African children. Paediatr Int Child Health 2012 0.84
137 3-monthly azithromycin administration for trachoma. Lancet 2009 0.84
138 Apnea and its possible relationship to immunization in ex-premature infants. Vaccine 2008 0.84
139 Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000-2005. Int J Antimicrob Agents 2008 0.84
140 Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002 0.83
141 Impact of haemophilus influenzae type b conjugate vaccine in South Africa and Argentina. Pediatr Infect Dis J 2004 0.83
142 Future challenges in the elimination of bacterial meningitis. Vaccine 2012 0.83
143 Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC Infect Dis 2010 0.83
144 Heterogeneous macrolide resistance and gene conversion in the pneumococcus. Antimicrob Agents Chemother 2006 0.83
145 Genotypic comparison of invasive Neisseria meningitidis serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. J Clin Microbiol 2009 0.83
146 Trimethoprim-sulfamethoxazole prophylaxis and antibiotic nonsusceptibility in invasive pneumococcal disease. Antimicrob Agents Chemother 2012 0.83
147 Molecular characterization of emerging non-levofloxacin-susceptible pneumococci isolated from children in South Africa. J Clin Microbiol 2009 0.82
148 The case for launch of an international DNA-based birth cohort study. J Glob Health 2011 0.82
149 Pneumococcal polysaccharide vaccine efficacy and routine use of conjugate vaccines in infants: there is no need for a vaccine program in older adults at present. Clin Infect Dis 2012 0.82
150 Bacterial Density, Serotype Distribution and Antibiotic Resistance of Pneumococcal Strains from the Nasopharynx of Peruvian Children Before and After Pneumococcal Conjugate Vaccine 7. Pediatr Infect Dis J 2016 0.81
151 Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol 2010 0.81
152 Bacterial aetiology of non-resolving otitis media in South African children. J Laryngol Otol 2003 0.81
153 Susceptibility of Bacillus anthracis to eleven antimicrobial agents including novel fluoroquinolones and a ketolide. J Antimicrob Chemother 2003 0.81
154 Mortality in penicillin-resistant pneumococcal meningitis. Pediatr Infect Dis J 2008 0.80
155 Surveillance for antimicrobial drug resistance in under-resourced countries. Emerg Infect Dis 2014 0.79
156 Capsule homology does not increase the frequency of transformation of linked penicillin binding proteins PBP 1a and PBP 2x in Streptococcus pneumoniae. Antimicrob Agents Chemother 2005 0.79
157 Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688. J Clin Microbiol 2012 0.79
158 Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. Antimicrob Agents Chemother 2007 0.79
159 Epidemiology of Serotype 1 Invasive Pneumococcal Disease, South Africa, 2003-2013. Emerg Infect Dis 2016 0.79
160 Nasopharyngeal Pneumococcal Density and Evolution of Acute Respiratory Illnesses in Young Children, Peru, 2009-2011. Emerg Infect Dis 2016 0.78
161 Editorial: Breathing new life into pneumonia epidemiology. Am J Epidemiol 2009 0.78
162 Antihypertensives suppress the emergence of fluoroquinolone-resistant mutants in pneumococci: an in vitro study. Int J Med Microbiol 2013 0.78
163 Streptococcus pneumoniae bacteraemia: pharmacodynamic correlations with outcome and macrolide resistance--a controlled study. Int J Antimicrob Agents 2007 0.78
164 Risk factors for invasive pneumococcal disease among children less than 5 years of age in a high HIV prevalence setting, South Africa, 2010 to 2012. Pediatr Infect Dis J 2015 0.78
165 Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States. BMC Infect Dis 2013 0.77
166 Invasive Neisseria meningitidis with decreased susceptibility to fluoroquinolones in South Africa, 2009. J Antimicrob Chemother 2010 0.77
167 Benefits to mother and child of influenza vaccination during pregnancy. Hum Vaccin Immunother 2012 0.77
168 Marking November 12, 2010 - World Pneumonia Day: where are we, where are vaccines? Hum Vaccin 2010 0.76
169 Single report of β-lactam resistance in an invasive Haemophilus influenzae isolate from South Africa mediated by mutations in penicillin-binding protein 3, 2003-2008. Int J Antimicrob Agents 2010 0.76
170 International pneumococcal clones match or exceed the fitness of other strains despite the accumulation of antibiotic resistance. Antimicrob Agents Chemother 2011 0.76
171 Population snapshot of invasive serogroup B meningococci in South Africa from 2005 to 2008. J Clin Microbiol 2012 0.76
172 Vaccination: a novel approach to reduce antibiotic resistance. Clin Infect Dis 2004 0.75
173 No impact of penicillin resistance on mortality. Clin Infect Dis 2006 0.75
174 Nasopharyngeal carriage of pneumococcal pediatric serotypes: a risk for acute and recurrent otitis media in children and for invasive disease in susceptible adults. J Infect Dis 2005 0.75
175 Clinical and microbiological features of invasive nontyphoidal Salmonella associated with HIV-infected patients, Gauteng Province, South Africa. Medicine (Baltimore) 2017 0.75
176 Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. BMC Infect Dis 2012 0.75
177 One enzyme inactivates two antibiotics. Nat Med 2006 0.75
178 Failures of beta-lactam therapy for invasive pneumococcal disease. Pediatr Infect Dis J 2004 0.75
179 Correlation between erythromycin and azithromycin resistance in Streptococcus pneumoniae. S Afr Med J 2003 0.75
180 Imputing direct and indirect vaccine effectiveness of childhood pneumococcal conjugate vaccine against invasive disease by surveying temporal changes in nasopharyngeal pneumococcal colonization. Am J Epidemiol 2017 0.75
181 In vitro activity of faropenem against respiratory pathogens. J Antimicrob Chemother 2002 0.75
182 Antibiotic prescribing practices for common childhood illnesses in South Africa. S Afr Med J 2003 0.75
183 A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. Int J Antimicrob Agents 2008 0.75